MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Nonsquamous NSCLC Progressing On or After Checkpoint Inhibitor Therapy or Chemotherapy
Kai He(The Ohio State University), Ticiana Leal(University of Wisconsin Carbone Cancer Center), Anthony Pham(Nebraska Cancer Specialists), Donald Richards(The US Oncology Network), Wade T. Iams(Vanderbilt University Medical Center), Shirish M. Gadgeel(Chinese University of Hong Kong), David S. Hong(The University of Texas MD Anderson Cancer Center), David Berz(Los Angeles Clinical Trials), Manish R. Patel(University of Minnesota Medical Center), Peter Olson(RIKEN BioResource Research Center), Alexander I. Spira(Virginia Cancer Specialists), Lisa Latven(Mirati Therapeutics (United States)), Robert M. Jotte(Sarah Cannon), Ronald Shazer(Mirati Therapeutics (United States)), David Waterhouse(Oncology Hematology Care), Edward B. Garon(University of California, Los Angeles), Xiaohong Yan(Mirati Therapeutics (United States)), Anne M. Traynor(University of Wisconsin Carbone Cancer Center), Débora S. Bruno(University Hospitals Cleveland Medical Center), Collin M. Blakely(City College of San Francisco)
Cited by 38
Related Papers
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Alectinib versus Crizotinib in Untreated <i>ALK</i>-Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2017|2.4k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k
Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA
|Annals of Oncology|2020|1.5k